DOCSLIB.ORG

Immunization Against Infectious Disease 1968

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunization Against Infectious Disease 1968 NCDC immunization against infectious disease 1968 U.S. DEPARTMENT OF HEALTH. EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE ' HealtLServices and Mental Health Administration YJ, >S i National Communicable Disease Center - Atlanta, Georgia 30333 National Communicable Disease Center Library Atlanta, Georgia 30333 Contents Page FOREWORD .................................................................................... 1 INTRODUCTION ........................................................................... 2 CURRENT REVIEWS-SELECTED INFECTIOUS DISEASES 3 Diphtheria................................................................. 5 Tetanus.................................................................... 8 Pertussis (Whooping Cough) .................................. 10 Measles (Rubeola)................................................. 12 Mumps ...................................................................... 17 'Poliomyelitis ............................................................ 20 Rubella (German M easles).................................... 26 C holera ................................................................... 29 Viral Hepatitis......................................................... 30 Influenza................................................................. 32 Plague.............................................................. .. 34 R abies.................................................................... 36 Smallpox............................................ , .................... 40 Tuberculosis............................................................ 44 BCG Vaccination................................................. 49 Preventive Treatment for Tuberculous Infection 51 Typhoid F ever......................................................... 52 Epidemic Typhus F ever......................................... 54 Yellow Fever .............■.......................................... 55 UNITED STATES IMMUNIZATION SURVEY, 1967-1968 SUMMARY 61 BIOLOGICS SURVEILLANCE, 1965-1968 SUMMARY ....................... 93 RECOMMENDATIONS-PHS ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES............................................................. 97 Cholera Vaccine.............................................................................. 101 Diphtheria and Tetanus Toxoids and Pertussis Vaccines.......... 103 Immune Serum Globulin for Prevention of Viral Hepatitis.......... 106 Influenza Vaccine—1969-70............................................................ 109 Measles V accine............................................................................ 111 Mumps V accine.............................................................................. 114 Plague Vaccine.............................................................................. 116 _ Poliomyelitis Vaccines ................................................................. 118 Rabies Prophylaxis ...................................................................... 120 Rubella Virus Prelicensing Statement.......................................... 124 Smallpox Vaccine............................................................................ 126 Typhoid V accine........................................................................... 131 Typhus Vaccine.............................................................................. 133 Yellow Fever Vaccine.................................................................... 135 435*0 Acknowledgments and Sources of Data \ Immunization Against Infectious Disease represents a NCDC as part of the established National Morbidity Re­ collaborative effort of various investigators in several porting System and are tabulated in the Morbidity and Programs and Branches of the National Communicable Mortality Weekly Report (MMWR), published regularly Disease Center, selected by the editor because of their by the Center. Official mortality data are provided by familiarity with specific diseases. It was originally devel­ the National Center for Health Statistics (NCHS). Wash­ oped in the Office of the Center Director, based on data ington, D.C. collected by the Epidemiology, Smallpox Eradication, Collecting information on individual cases of selected Foreign Quarantine, and Ecological Investigations Pro­ diseases, such as poliomyelitis and diphtheria, is a sur­ grams, the Laboratory Division, and the Immunization veillance activity of various Programs at the NCDC. This and Tuberculosis Branches of the State and Community information comes through epidemiologic and labora­ Services Division. Credit is due the staff of Statistical tory reporting channels from State and other health jur­ Services Activity of Epidemiology Program for efforts to isdictions. Surveillance data on cases of specific com­ ensure completeness and accuracy of data. Special credit municable diseases form a very useful resource for is due Miss Frances Porcher, chief of Epidemiology Pro­ careful analysis of disease trends. Case counts from sur­ gram’s editorial-graphics staff, who acted as the man­ veillance activities may not always match the official aging editor. The diligence of all participants is gratefully totals because of the inherently different mechanisms of acknowledged. collection. It should be noted that the official data Data in Immunization Against Infectious Disease are (MMWR, NCHS) are the authoritative and archival derived from official reports submitted by States and counts of cases and deaths, but surveillance records pro­ other reporting health jurisdictions. Weekly tallies of the vide additional insights on trends and patterns of com­ numbers of cases of reportable diseases are sent to the municable diseases and therefore merit attention. Foreword The Public Health Service Advisory Committee on Immunization Practices encouraged the National Communicable Disease Center to undertake the preparation and development o f a handbook Immunizationon Against Infec­ tious Disease. In their deliberations on communicable disease trends and the optimal role of immunizations, members of the committee agreed that a meaningful analysis o f achievements and current objectives should be made generally available to the country’s public health workers, students o f medi­ cine, and physicians in private practice and in academic medicine. And per­ haps more importantly, they recommended placing under one cover perti­ nent material bearing on this subject from several sources. This summary covers the basic communicable diseases in which effective vaccines play an important role. In future editions, additional subjects may be covered to provide a more comprehensive background for sound pre­ ventive medical practice. Readers are encouraged to submit comments and suggestions to the editor for improving this handbook, to make it as useful as possible to the profes­ sions that find this information helpful. J. Lyle Conrad, M.D. Editor INTRODUCTION In recent decades, effective vaccines have become ma­ all elements necessary for the development of a meaning­ jor resources of preventive medicine. Except for antigens ful immunization pattern. , of vaccinia and rabies, there were no effective vaccines This edition of Immunization Against Infectious Dis- ' for common infectious diseases until relatively recently. ease is a review of the status of infectious diseases impor- Use of the variety of inactivated vaccines and live a tte n ­ tant to the United States and for which there are effec­ uated antigens has resulted in dramatic control of several tive immunizing agents. The depth of analysis, scope of diseases in the United States. coverage, and general level of detail will undoubtedly There has not been one confirmed case of smallpox in change with added insights and new sources of informa­ this country in 20 years, poliomyelitis is under control, tion. This edition, primarily covering data summarized measles incidence is at its lowest point in history, and through the 1968 calendar year, is addressed to the stu­ diphtheria and tetanus are on the wane. In the future, we dents of public health and medicine; it assesses for them can expect mumps, rubella, and other common infec­ not only achievements in control but also their obliga­ tious diseases to be controlled or eliminated as public tions toward maintaining alertness to present and future health problems, through the use of vaccines currently needs. available or under development. The contents of this summary are divided into three This immunological basis of preventive medicine im­ major sections: The first deals with the status of major plies, however, a major responsibility for the public communicable diseases and the effects of vaccines on health and medical professions. Along with the luxury them. The second section contains summaries of the and ease of health provided by artificial antigens must go United States Immunization Survey, which is sponsored the commitment for maintaining careful, intensive by the National Communicable Disease Center and car­ watch — “surveillance” — on their performance. The ried out annually by the Bureau of the Census, and the scope of surveillance ranges from determining the popu­ 1968 Biologies Surveillance Summary, a collaborative ef­ lation’s level of protection to assessing the relative ef­ fort of the major producers of biologies in the United fectiveness of alternative antigens. States and the NCDC. The third section contains the Vaccines with short durations of protection could Recommendations of the Public Health Service Advisory merely postpone
Load more

Recommended publications
  • RNA-Based Adjuvant CV8102 Enhances the Immunogenicity of a Licensed Rabies Vaccine in a first-In-Human Trial
    Vaccine 37 (2019) 1819–1826 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial Fatma Doener a,1, Henoch S. Hong a,1, Ingo Meyer b,1, Keyvan Tadjalli-Mehr c, Angelika Daehling c, ⇑ Regina Heidenreich a, Sven D. Koch a, Mariola Fotin-Mleczek a, Ulrike Gnad-Vogt c, a Curevac AG, Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany b CRS Clinical Research Services Mönchengladbach GmbH, 41061 Mönchengladbach, Germany c Curevac AG, Schumannstrasse 27, 60325 Frankfurt, Germany article info abstract Article history: Background: We report the first-in-concept human trial of the safety, tolerability and immunogenicity Received 27 September 2018 when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with Received in revised form 30 January 2019 fractional doses of a licensed rabies vaccine (RabipurÒ) as model antigen. Accepted 3 February 2019 Methods: The primary objective was to assess the safety and reactogenicity of various dose levels of Available online 21 February 2019 CV8102 alone or mixed with RabipurÒ in healthy 18–40 year-old male volunteers. A secondary objective was to assess the immune-enhancing potential of bedside-mixes of CV8102 with fractional doses of Keywords: Ò Rabipur by measuring induction of rabies virus neutralising titres (VNTs). Adjuvant Results: Fifty-six volunteers received 50–100 lg CV8102 alone (n = 11), bedside-mixed CV8102 and RNA Ò Ò Ò Rabies Rabipur (n = 20), or Rabipur alone (n = 25; control).
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • ID 2 | Issue No: 4.1 | Issue Date: 29.10.14 | Page: 1 of 24 © Crown Copyright 2014 Identification of Corynebacterium Species
    UK Standards for Microbiology Investigations Identification of Corynebacterium species Issued by the Standards Unit, Microbiology Services, PHE Bacteriology – Identification | ID 2 | Issue no: 4.1 | Issue date: 29.10.14 | Page: 1 of 24 © Crown copyright 2014 Identification of Corynebacterium species Acknowledgments UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk- standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical- laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations- steering-committee). The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content. For further information please contact us at: Standards Unit Microbiology Services Public Health England 61 Colindale Avenue London NW9 5EQ E-mail: [email protected] Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality- and-consistency-in-clinical-laboratories UK Standards for Microbiology Investigations are produced in association with: Logos correct at time of publishing. Bacteriology – Identification | ID 2 | Issue no: 4.1 | Issue date: 29.10.14 | Page: 2 of 24 UK Standards for Microbiology Investigations | Issued by the Standards Unit, Public Health England Identification of Corynebacterium species Contents ACKNOWLEDGMENTS .........................................................................................................
    [Show full text]
  • The Influence of Social Conditions Upon Diphtheria, Measles, Tuberculosis and Whooping Cough in Early Childhood in London
    VOLUME 42, No. 5 OCTOBER 1942 THE INFLUENCE OF SOCIAL CONDITIONS UPON DIPHTHERIA, MEASLES, TUBERCULOSIS AND WHOOPING COUGH IN EARLY CHILDHOOD IN LONDON BY G. PAYLING WRIGHT AND HELEN PAYLING WRIGHT, From the Department of Pathology-, Guy's Hospital Medical School (With 1 Figure in the Text) Before the war diphtheria, measles, tuberculosis and whooping cough were the most important of the better-defined causes of death amongst young children in the London area. The large numbers of deaths registered from these four diseases in the age group 0-4 years in the Metropolitan Boroughs alone between 1931 and 1938, together with the deaths recorded under bronchitis and pneumonia, are set out in Table 1. These records Table 1. Deaths from diphtheria, measles, tuberculosis (all forms), whooping cough, bron- chitis and pneumonia amongst children, 0-4 years, in the Metropolitan Boroughs from 1931 to 1938 Whooping Year Diphtheria Measles Tuberculosis cough Bronchitis Pneumonia 1931 148 109 184 301 195 1394 1932 169 760 207 337 164 1009 1933 163 88 150 313 101 833 1934 232 783 136 ' 277 167 1192 1935 125 17 108 161 119 726 1936 113 539 122 267 147 918 1937 107 21 100 237 122 827 1938 90 217 118 101 109 719 for diphtheria, measles, tuberculosis and whooping cough fail, however, to show all the deaths that should properly be ascribed to these specific diseases. For the most part, the figures represent the deaths occurring during their more acute stages, and necessarily omit some of the many instances in which these infections, after giving rise to chronic disabilities, terminate fatally from some less well-specified cause.
    [Show full text]
  • USDA-Approved Animal Rabies Vaccines
    United States Department of Agriculture (USDA) Approved Animal Rabies Vaccines Table 1. Rabies Vaccines Licensed and Marketed in the United States, 2016 Age at For use Route of Product Name Produced by Marketed by Dose primary Booster vaccination in inoculation vaccination* A) MONOVALENT (Inactivated) RAB RABVAC 1 Boehringer Boehringer Dogs 1 ml 3 months Annually IM or SC Ingelheim Ingelheim Vetmedica Cats 1 ml 3 months Annually IM or SC Vetmedica Inc Inc License No. 124 RABVAC 3 Boehringer Boehringer Dogs 1 ml 3 months 1 year later & triennially IM or SC Ingelheim Ingelheim Vetmedica Cats 1 ml 3 months 1 year later & triennially IM or SC Vetmedica Inc Inc Horses 2 ml 3 months Annually IM License No. 124 EQUIRAB with Merck Animal Merck Animal Health Horses 1 ml 4 months Annually IM Havlogen Health License No. 165A DEFENSOR 1 Zoetis Zoetis Dogs 1 ml 3 months Annually IM or SC License No. 190 Cats 1 ml 3 months Annually SC DEFENSOR 3 Zoetis Zoetis Dogs 1 ml 3 months 1 year later & triennially IM or SC License No. 190 Cats 1 ml 3 months 1 year later & triennially SC Sheep 2 ml 3 months Annually IM Cattle 2 ml 3 months Annually IM NOBIVAC: 1- Zoetis Merck Animal Health Dogs 1 ml 3 months Annually IM or SC Rabies License No. 190 Cats 1 ml 3 months Annually SC NOBIVAC: 3- Zoetis Merck Animal Health Dogs 1 ml 3 months 1 year later & triennially IM or SC Rabies and 3- License No. 190 Cats 1 ml 3 months 1 year later & triennially SC Rabies CA Sheep 2 ml 3 months Annually IM Cattle 2 ml 3 months Annually IM IMRAB 1 Merial, Inc Merial, Inc Dogs 1 ml 3 months Annually SC License No.
    [Show full text]
  • The Clinical Features of Smallpox
    CHAPTER 1 THE CLINICAL FEATURES OF SMALLPOX Contents Page Introduction 2 Varieties of smallpox 3 The classification of clinical types of variola major 4 Ordinary-type smallpox 5 The incubation period 5 Symptoms of the pre-eruptive stage 5 The eruptive stage 19 Clinical course 22 Grades of severity 22 Modified-type smallpox 22 Variola sine eruptione 27 Subclinical infection with variola major virus 30 Evidence from viral isolations 30 Evidence from serological studies 30 Flat-type smallpox 31 The rash 31 Clinical course 32 Haemorrhagic-type smallpox 32 General features 32 Early haemorrhagic-type smallpox 37 Late haemorrhagic-type smallpox 38 Variola minor 38 Clinical course 38 Variola sine eruptione and subclinical infection 40 Smallpox acquired by unusual routes of infection 40 Inoculation variola and variolation 40 Congenital smallpox 42 Effects of vaccination on the clinical course of smallpox 42 Effects of vaccination on toxaemia 43 Effects of vaccination on the number of lesions 43 Effects of vaccination on the character and evolution of the rash 43 Effects of vaccination in variola minor 44 Laboratory findings 44 Virological observations 44 Serological observations 45 Haematological observations 46 1 2 SMALLPOX AND ITS ERADICATION Page Complications 47 The skin 47 Ocular system 47 Joints and bones 47 Respiratory system 48 Gastrointestinal system 48 Genitourinary system 49 Central nervous system 49 Sequelae 49 Pockmarks 49 Blindness 50 Limb deformities 50 Prognosis of variola major 50 Calculation of case-fatality rates 50 Effects
    [Show full text]
  • Elizabeth Gyamfi
    University of Ghana http://ugspace.ug.edu.gh GENOTYPING AND TREATMENT OF SECONDARY BACTERIAL INFECTIONS AMONG BURULI ULCER PATIENTS IN THE AMANSIE CENTRAL DISTRICT OF GHANA BY ELIZABETH GYAMFI (10442509) THIS THESIS IS SUBMITTED TO THE UNIVERSITY OF GHANA, LEGON IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF A MASTER OF PHILOSOPHY DEGREE IN MEDICAL BIOCHEMISTRY JULY, 2015 University of Ghana http://ugspace.ug.edu.gh DECLARATION I ELIZABETH GYAMFI, do hereby declare that with the exception of references to other people’s work, which have been duly acknowledged, this thesis is the outcome of my own research conducted at the Department of Medical Biochemistry, University of Ghana Medical School, College of Health Sciences and the Department of Cell, Molecular Biology and Biochemistry, University of Ghana, College of Basic and Applied Science under the supervision of Dr. Lydia Mosi and Dr. Bartholomew Dzudzor. Neither all nor parts of this project have been presented for another degree elsewhere. ……………………………………………. Date: ………………………. ELIZABETH GYAMFI (Student) ……………………………………………. Date: ………………………… DR. LYDIA MOSI (Supervisor) ………………………………………….. Date: ……………………….. DR. BATHOLOMEW DZUDZOR (Supervisor) i University of Ghana http://ugspace.ug.edu.gh ABSTRACT Background Buruli ulcer (BU) is a skin disease caused by Mycobacterium ulcerans. BU is the third most common mycobacterial disease after tuberculosis and leprosy, but in Ghana and Cote d’ Ivoire, it is the second. M. ulcerans produces mycolactone, an immunosuppressant macrolide toxin which makes the infection painless. However, some patients have complained of painful lesions and delay healing. Painful ulcers and delay healing experienced by some patients may be due to secondary bacterial infections. Main Objective: To identify secondary microbial infections of BU patients, their genetic diversity as well as determine the levels of antibiotics resistance of these microorganisms.
    [Show full text]
  • SUPPLEMENT Collected Recommendations of the Public Health Service Advisory Committee on Immunization Practices
    SUPPLEMENT Collected Recommendations of the Public Health Service Advisory Committee on Immunization Practices The Public Health Service Advisory Committee on The Committee has reviewed all of its statements Immunization Practices has in the last 5 years made within the past several months. Only minor revisions and recommendations concerning the use of vaccines and editorial changes were made. No substantive modifica­ other biologies in the prevention of 16 diseases. Each tions resulted from this annual review. Each of the state­ statement by the AC IP is regularly published in the ments carries the dates of original publication and past Morbidity and Mortality Weekly Report upon com­ revisions. pletion or revision. For the first time, a brief list of selected references is The full series of recommendations has never been appended to each statement. These bibliographies are printed as a single document. However, it was felt that a not meant to be definitive, but are a starting point for supplement to the MMWR incorporating all of the exis­ more extensive review of the pertinent literature on the ting ACIP recommendations would be a useful reference. disease, the vaccine, and its appropriate uses. CONTENTS Page 3 - Cholera Vaccine 4 - Diphtheria and Tetanus Toxoids and Pertussis Vaccine 6 - Immune Serum Globulin for Prevention of Viral Hepatitis 9 - Influenza Vaccine-1969-70 10 - Measles Vaccines 12 - Mumps Vaccine 14 - Plague Vaccine 15 - Poliomyelitis Vaccines 17 - Rabies P rophylaxis 21 - Rubella Virus Vaccine Prelicensing Statement 23 - Smallpox Vaccine 26 - Typhoid Vaccine 27 - Typhus Vaccine 28 - Yellow Fever Vaccine PUBLIC HEALTH SERVICE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES Since its establishment in 1964, the Public Health ences in emphasis have not been felt to compromise the Service Advisory Committee on Immunization Practices goal of achieving immunity in vaccinees.
    [Show full text]
  • Nih Guidelines for Research Involving Recombinant Or Synthetic Nucleic Acid Molecules (Nih Guidelines)
    NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT OR SYNTHETIC NUCLEIC ACID MOLECULES (NIH GUIDELINES) APRIL 2019 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health ************************************************************************************************************************ Visit the NIH OSP Web site at: https://osp.od.nih.gov NIH OFFICE OF SCIENCE POLICY CONTACT INFORMATION: Office of Science Policy, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), (301) 496-9838; (301) 496-9839 (fax). For inquiries, information requests, and report submissions: [email protected] These NIH Guidelines shall supersede all earlier versions until further notice. ************************************************************************************************************************ Page 2 - NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (April 2019) FEDERAL REGISTER NOTICES Effective June 24, 1994, Published in Federal Register, July 5, 1994 (59 FR 34472) Amendment Effective July 28, 1994, Federal Register, August 5, 1994 (59 FR 40170) Amendment Effective April 17, 1995, Federal Register, April 27, 1995 (60 FR 20726) Amendment Effective December 14, 1995, Federal Register, January 19, 1996 (61 FR 1482) Amendment Effective March 1, 1996, Federal Register, March 12, 1996 (61 FR 10004) Amendment Effective January 23, 1997, Federal Register, January 31, 1997 (62 FR 4782) Amendment Effective September 30, 1997,
    [Show full text]
  • Oklahoma Disease Reporting Manual
    Oklahoma Disease Reporting Manual List of Contributors Acute Disease Service Lauri Smithee, Chief Laurence Burnsed Anthony Lee Becky Coffman Renee Powell Amy Hill Jolianne Stone Christie McDonald Jeannie Williams HIV/STD Service Jan Fox, Chief Kristen Eberly Terrainia Harris Debbie Purton Janet Wilson Office of the State Epidemiologist Kristy Bradley, State Epidemiologist Public Health Laboratory Garry McKee, Chief Robin Botchlet John Murray Steve Johnson Table of Contents Contact Information Acronyms and Jargon Defined Purpose and Use of Disease Reporting Manual Oklahoma Disease Reporting Statutes and Rules Oklahoma Statute Title 63: Public Health and Safety Article 1: Administration Article 5: Prevention and Control of Disease Oklahoma Administrative Code Title 310: Oklahoma State Department of Health Chapter 515: Communicable Disease and Injury Reporting Chapter 555: Notification of Communicable Disease Risk Exposure Changes to the Communicable Disease and Injury Reporting Rules To Which State Should You Report a Case? Public Health Investigation and Disease Detection of Oklahoma (PHIDDO) Public Health Laboratory Oklahoma State Department of Health Laboratory Services Electronic Public Health Laboratory Requisition Disease Reporting Guidelines Quick Reference List of Reportable Infectious Diseases by Service Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS) Anthrax Arboviral Infection Bioterrorism – Suspected Disease Botulism Brucellosis Campylobacteriosis CD4 Cell Count < 500 Chlamydia trachomatis,
    [Show full text]
  • Effectiveness of a Monovalent Human Rotavirus Vaccine Among Children of 5 Years and Under in Kwazulu-Natal Osaretin Emmanuel
    EFFECTIVENESS OF A MONOVALENT HUMAN ROTAVIRUS VACCINE AMONG CHILDREN OF 5 YEARS AND UNDER IN KWAZULU-NATAL OSARETIN EMMANUEL ASOWATA SUBMITTED IN FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (MEDICAL MICROBIOLOGY) IN THE SCHOOL OF LABORATORY MEDICINE AND MEDICAL SCIENCES, UNIVERSITY OF KWAZULU-NATAL, SOUTH AFRICA FEBRUARY, 2016 i PREFACE Diarrhoeal disease is one of the leading cause of morbidity and mortality among children of 5 years and under in South Africa. Rotaviruses have been documented as causing one-third of all diarrhoea hospital admissions. Vaccination is the main public health intervention to prevent and control rotavirus infections. Two oral live-attenuated rotavirus vaccines has been has been licensed for global use and one of these vaccines has been included in the national immunization programme of South Africa since August 2009. However, rotavirus remains a major aetiology of diarrhoea in infants and young children in South Africa. Clinical trials in South Africa have reported a low effectiveness of this vaccine in comparison to that reported from high income countries. Reasons for the reduced effectiveness of the rotavirus vaccine seen locally are speculative. The ability of this vaccine to protect against emerging strains of rotavirus is not fully understood. This study was conducted to evaluate possible factors influencing the effectiveness of the rotavirus vaccine on Kwazulu-Natal, South Africa. ii DECLARATION This work was carried out by me, Osaretin Emmanuel Asowata. It has not been submitted in any form to the University of KwaZulu-Natal or any other tertiary institution for degree award purposes. All experiments was carried out in the department of Infection Prevention and Control, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal under the supervision of Professor Prashini Moodley and co-supervised by Dr.
    [Show full text]
  • Inactivated Japanese Encephalitis Virus Vaccine
    January 8, 1993 / Vol. 42 / No. RR-1 CENTERS FOR DISEASE CONTROL AND PREVENTION Recommendations and Reports Inactivated Japanese Encephalitis Virus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333 The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), Public Health Service, U.S. Depart- ment of Health and Human Services, Atlanta, Georgia 30333. SUGGESTED CITATION Centers for Disease Control and Prevention. Inactivated Japanese encephalitis vi- rus vaccine. Recommendations of the advisory committee on immunization practices (ACIP). MMWR 1993;42(No. RR-1):[inclusive page numbers]. Centers for Disease Control and Prevention .................... William L. Roper, M.D., M.P.H. Director The material in this report was prepared for publication by: National Center for Infectious Diseases..................................James M. Hughes, M.D. Director Division of Vector-Borne Infectious Diseases ........................Duane J. Gubler, Sc.D. Director The production of this report as an MMWR serial publication was coordinated in: Epidemiology Program Office.................................... Stephen B. Thacker, M.D., M.Sc. Director Richard A. Goodman, M.D., M.P.H. Editor, MMWR Series Scientific Information and Communications Program Recommendations and Reports ................................... Suzanne M. Hewitt, M.P.A. Managing Editor Sharon D. Hoskins Project Editor Rachel J. Wilson Editorial Trainee Peter M. Jenkins Visual Information Specialist Use of trade names is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services.
    [Show full text]